Zohydro ER, a controversial long-acting opioid that hit the market last year to cries of outrage, received government approval on the heels of a study with dubious conclusions as to the drug’s effectiveness at relieving pain, researchers have concluded.
When the U.S. Food and Drug Administration approved the long-acting pure hydrocodone pill in October 2013, critics pointed to the painkiller’s lack of abuse-deterrent properties and the 11-2 vote against greenlighting the drug from an FDA advisory council. Since then, the drug’s manufacturer has released an abuse-resistan...
Comments